Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented UNITY Biotechnology in the transaction. UNITY Biotechnology, Inc. (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Amgen in the offerings, while Shearman & Sterling represented represented the underwriters. Amgen Inc. executed a senior unsecured notes offerings consisting of US$1,250,000,000 4.050%...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Amgen in the offerings. Amgen Inc., one of the world’s leading biotechnology companies, priced on February 17, 2022, a senior unsecured notes...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Angion in the offering and private placement. Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering of 5...
You must be a Standard 1 Year member to access this content.
